BPC-157 vs VIP
Extensively Studied vs Extensively Studied
compatible No known negative interactions; different mechanisms.
Molecular Data
BPC-157 VIP
Weight 1,419.53 Da 3,326 Da
Half-life <30 minutes 1-2 minutes
Chain 15 amino acids 28 amino acids
Type Pentadecapeptide Neuropeptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
VIP
01 Potent vasodilation and blood pressure reduction
02 Strong anti-inflammatory effects
03 Immunomodulation (Th1-Th2 balance)
04 Neuroprotective effects
05 Bronchodilation
06 Cardioprotective (positive inotropic effects)
07 Insulin secretion enhancement (glucose-dependent)
08 Gut barrier and permeability regulation
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
VIP
50-100 mcg per dose (up to 200 mcg in research protocols) / 1-2 times daily due to very short 2-minute half-life
General use 50-100 mcg 1-2x daily
Research protocols 100-200 mcg As directed
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
VIP
Vasodilation (flushing, warmth)
Hypotension
Increased heart rate
Gastrointestinal effects (diarrhea possible)
Headache
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Severe hypotension
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
Research Evidence
BPC-157 VIP
Status Extensively Studied Extensively Studied
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.